Paolo Crivelli Email & Phone Number

Milano

I am Leading the EMEA Marketing Operations, including the coordination of the Strategic plan, the definition of the Marketing mix, product launches and the priority tactics implementation. the Marketing Team works with a solid cross-functional collaboration the relevant departments, including, Sales, CAM, Medical affairs, Clinical Application, Market Access, Regulatory, QA, Legal, Finance

Italy And Belgium

Lead the Global Client Services Team that supports Pharmaceutical, Medical Device and IVD companies to extract the relevant science data and the clinical experience of thought leaders, using a unique systematic approach firmly founded in applied educational and behavioral science. Develop together with our clients and thought leaders the appropriate product positioning and overcome the barriers of adoption in order to develop and execute engaging communication/education solutions that… Show more Lead the Global Client Services Team that supports Pharmaceutical, Medical Device and IVD companies to extract the relevant science data and the clinical experience of thought leaders, using a unique systematic approach firmly founded in applied educational and behavioral science. Develop together with our clients and thought leaders the appropriate product positioning and overcome the barriers of adoption in order to develop and execute engaging communication/education solutions that are measurable and ensure lasting adoption. I also cover the role of Amministratore of Ismar Healthcare Italy S.r.l. Show less

Italy

Main Responsibilities: GLOBAL PORTFOLIO STRATEGY & PLANNING: Set the Medium and Long Term Plan for the Group, and the “Menu expansion strategy” including Value Pricing and the Investigational assays, in cooperation with the VP R&D, the CEO and the CCOVALUE PRICING: Created the “Value Pricing tools” to justify Premium Pricing by translating advantages of the DiaSorin Solutions in facts and numbers. This allowed, for example, prices for DiaSorin 1,25 Vitamin D and Calprotectin to… Show more Main Responsibilities: GLOBAL PORTFOLIO STRATEGY & PLANNING: Set the Medium and Long Term Plan for the Group, and the “Menu expansion strategy” including Value Pricing and the Investigational assays, in cooperation with the VP R&D, the CEO and the CCOVALUE PRICING: Created the “Value Pricing tools” to justify Premium Pricing by translating advantages of the DiaSorin Solutions in facts and numbers. This allowed, for example, prices for DiaSorin 1,25 Vitamin D and Calprotectin to exceed by up to 50% prices of competition and to capture strong Market Share gain. GLOBAL PRE-MARKETING and LAUNCH of LIAISON XS: defined design goals of the new benchtop analyzer, the first wave of assays x Region and the forecast for USA, Europe and China in Strategic Market Segments. Lead an interdisciplinary Team with R&D, Regulatory, Operations, Marketing.USA MARKETING STRATEGY and KEY PROGRAMS: Lead the US Marketing Team on key strategic programs such as the Liaison XS launch and the US Menu expansion (4 new assays in 2018)B2B STRATEGIC COLLABORATIONSLead the MKTG collaboration with Qiagen to expand the Liaison menu with selected Qiagen assays WWGLOBAL LAUNCH OF A CRM SYSTEM: redifined the group "Selling Cycle" and launched SalesForce.com to establish an harmonized approach in managing the client base, funnel, forecasting and monitor the Sales Force effectiveness.LEADERSHIP: I ensure cross-functional alignment and implementation of strategy establishing and nurturing a positive attitude behavior between departments. 3 direct reports at the HQ, 7 functional reports in the US. Show less

Stillwater, Minnesota, Usa

PEOPLE MANAGEMENT: restructured the US Marketing Team, building a Team of 8 people: implemented solid Sales & MKTG synergy to accelerate deals closing, add on opportunities, Sales Force effectiveness. In charge of market evaluations and MKT development studies to expand clinical utility of novel and/or underpenetrated assays. DISTRIBUTION AND BUSINESS AGREEMENTS MANAGEMENT:Led the Marketing relationship with existing Key Business Partners (Such as Sonic and Meridian) and National… Show more PEOPLE MANAGEMENT: restructured the US Marketing Team, building a Team of 8 people: implemented solid Sales & MKTG synergy to accelerate deals closing, add on opportunities, Sales Force effectiveness. In charge of market evaluations and MKT development studies to expand clinical utility of novel and/or underpenetrated assays. DISTRIBUTION AND BUSINESS AGREEMENTS MANAGEMENT:Led the Marketing relationship with existing Key Business Partners (Such as Sonic and Meridian) and National Accounts (Quest, LabCorp) in cooperation with the VP National Accounts, with a strong contribution to the revenue growth.PORTFOLIO STRATEGY Responsibility: Set the “USA menu expansion strategy”, with the US President, R&D, the CEO and the CCOSet the new launches strategy (positioning, pricing, key messages, 3 years sales targets) in cooperation with Corporate. Got approval for the US POL menu of 14 assays, PCT, Calprotectin.SALES and PRICING strategy:Setting of Pricing grids and Value Pricing tools. Deals profitability approval, together with the VP USA Sales. 1,25 Vitamin D launch reached results well above expectation such as the CLIA Ex Vitamin D Business, for 2 consecutive years. BUDGET HOLDER: for the USA Marketing investments Show less

Vercelli

PEOPLE MANAGEMENT: includes the WW responsibility for the Corporate Marketing Team: Mtkg Directors, Mktg Manager, Product Manager, Communication Manager, Business Analyist, Administrative Assistant. Functional reports, all Subsidiaries Marketing functions WW ( around 45 colleagues)B2B STRATEGIC COLLABORATIONS: managed key Business Partner negotiating directly cooperation and distribution agreements (Such the connectivity agreement with Roche Diagnostics, Meridian… Show more PEOPLE MANAGEMENT: includes the WW responsibility for the Corporate Marketing Team: Mtkg Directors, Mktg Manager, Product Manager, Communication Manager, Business Analyist, Administrative Assistant. Functional reports, all Subsidiaries Marketing functions WW ( around 45 colleagues)B2B STRATEGIC COLLABORATIONS: managed key Business Partner negotiating directly cooperation and distribution agreements (Such the connectivity agreement with Roche Diagnostics, Meridian, Tecan..)LAUNCHES and PORTFOLIO STRATEGY WW Responsibility: Implemented more than 25 launches in the period, contributing over $130M to the top line. Set the new launches strategy (positioning, pricing, 3 years sales targets) in the 5 commercial regions ( Italy, Europe, APAC and Export, North America, Latin America). Set the long term plan portfolio strategy, in cooperation with R&D, to be presented to the CEO, CCO, VP R&D.BUDGET HOLDER: for the WW Corporate Marketing expenses from Jan 2010 to mid 2011 I managed ad interim the Corp. Customer Care Team (12 people) Show less

Tolochenaz, Switzerland

ACTIVA Therapy is a Medical Device for Parkinson disease, Essential Tremor and Dystonia)Restructured the ACTIVA MKTG Team: 11 people – 4 Product Manager, 1 Administrative Assistant, the Procedure Solution Team of 5 Field Specialists plus 1 Product Manager.Implemented product launches, such as ACTIVA rechargeable and the future indications under evaluation (Depression, Epilepsy etc). ACTIVA rechargeable launched at double price compared to non-rechargeable, together with a MKT… Show more ACTIVA Therapy is a Medical Device for Parkinson disease, Essential Tremor and Dystonia)Restructured the ACTIVA MKTG Team: 11 people – 4 Product Manager, 1 Administrative Assistant, the Procedure Solution Team of 5 Field Specialists plus 1 Product Manager.Implemented product launches, such as ACTIVA rechargeable and the future indications under evaluation (Depression, Epilepsy etc). ACTIVA rechargeable launched at double price compared to non-rechargeable, together with a MKT development referral program, resulted in 25% growth in new patients, and above expectation revenue growth in year 1Brand Team: the role includes the direct responsibility of the Marketing, Reimbursement and Phase IV Clinical budget. Functional reports: Two Clinical Manager, Reimbursement Manager, Communication Manager, Education manager, Business Analyst, Finance manager, Regulatory manager, Supply Chain Manager. European representative in the Global Marketing Task Force Show less

Tolochenaz, Switzerland

Head of Gastroenterology & Urology Divisions (Head of MGU MKTG) in MedtronicMGU turnover of 200$ millions worldwide, and growth rate above 25% Portfolio: includes devices from Medtronic research and companies acquisitions: InterStim, sacral nerve stimulation for urinary and faecal incontinence; TUNA for patients with BPH; Gatekeeper, for patients with gastro-esophageal reflux, Enterra, for patients with diabetic and idiopathic gastroparesis.Restructured the MKTG Team:… Show more Head of Gastroenterology & Urology Divisions (Head of MGU MKTG) in MedtronicMGU turnover of 200$ millions worldwide, and growth rate above 25% Portfolio: includes devices from Medtronic research and companies acquisitions: InterStim, sacral nerve stimulation for urinary and faecal incontinence; TUNA for patients with BPH; Gatekeeper, for patients with gastro-esophageal reflux, Enterra, for patients with diabetic and idiopathic gastroparesis.Restructured the MKTG Team: Direct reports: four Product Manager. Functional reports: Two Clinical Manager, Reimbursement Manager, Communication Manager, Statistician. Responsibility expanded to Sales Analysis and Sales Forecasting in 2005. A step into Sales, to support and challenge the countries to increase the number of won deals, and set appropriate Sales objectives. I created a funnel tool to ensure: resources focus, increase competitiveness and Sales Force effectiveness, through timely identification of risk and opportunities, development of programs that fully fit Business needs Show less

Leiderdorp, The Netherlands

Responsible for setting the strategy and implementing the marketing support for OMNIC in both Europe and EMEA. OMNIC with a turnover of 280 million Euro was Yamanouchi Europe’s best selling brand accounting for more than 50% of the company’s revenue. Delivered a €40M growth, growing the share of Urologists prescriptions and reinforcing MKTG programs in key countries like Germany, France and Spain.Developed the OMNIC Brand Team of 8. 1 PM, 1 admin. Functional reports: 2 Medical Managers,… Show more Responsible for setting the strategy and implementing the marketing support for OMNIC in both Europe and EMEA. OMNIC with a turnover of 280 million Euro was Yamanouchi Europe’s best selling brand accounting for more than 50% of the company’s revenue. Delivered a €40M growth, growing the share of Urologists prescriptions and reinforcing MKTG programs in key countries like Germany, France and Spain.Developed the OMNIC Brand Team of 8. 1 PM, 1 admin. Functional reports: 2 Medical Managers, Regulatory Manager, Marketing Intelligence Manager, Health Economics Manager, Clinical Trials Coordinator. Show less

Milan (It) And Leiderdorp (Nl)

P&L responsibility for the BU with revenue of €70M2000-2001. Support the development of the European OMNIC strategy and responsibility of the 2001 Urology Summit Meeting in New York, the largest KOL meeting organized in Urology). Achieved large KOL endorsement and a stream of new publications which supported increased prescriptions from GPs . Project Leader for the “Budget Control” project, set up to integrate F&A and Marketing investment control models… Show more P&L responsibility for the BU with revenue of €70M2000-2001. Support the development of the European OMNIC strategy and responsibility of the 2001 Urology Summit Meeting in New York, the largest KOL meeting organized in Urology). Achieved large KOL endorsement and a stream of new publications which supported increased prescriptions from GPs . Project Leader for the “Budget Control” project, set up to integrate F&A and Marketing investment control models. For the one year, added responsibility for Gastroenterlolgy to prepare the launch of INFERGEN, Consensus Interferon to treat Hepatitis C Show less

Milano, Italia

Execution of OMNIC launch, a drug for Benign Prostatic Hyperplasia co-marketed with Boehringer Ingelheim. OMNIC became leader in the alpha blocker segment five months after launch and class market leader 18 months after launch, exceeding €40M sales. Yamanouchi Italy was the best performing market in EU.

Degree In Pharmacy, Pharmacy And Pharmacology, 110/110

Postgraduate Course In Leadership Capabilities